Mario Scartozzi
A5034035272- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Metastasis and carcinoma case studies
- Colorectal Cancer Surgical Treatments
- Gallbladder and Bile Duct Disorders
- Liver Disease Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Metabolism and Genetic Disorders
- PI3K/AKT/mTOR signaling in cancer
- Angiogenesis and VEGF in Cancer
- Cancer Diagnosis and Treatment
- Pulmonary Hypertension Research and Treatments
- Inflammatory Biomarkers in Disease Prognosis
University of Cagliari
2016-2025
Azienda Ospedaliero-Universitaria Cagliari
2016-2025
Policlinico Casilino
2021-2024
Istituto Nazionale di Fisica Nucleare, Sezione di Cagliari
2023
Samsung Medical Center
2023
Sungkyunkwan University
2023
Vita-Salute San Raffaele University
2022-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2023
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2023
CHA Bundang Medical Center
2023
PTEN, AKT, and KRAS are epidermal growth factor receptor (EGFR) downstream regulators. mutations confer resistance to cetuximab. This retrospective study investigated the role of PTEN loss, AKT phosphorylation, on activity cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC).A cohort irinotecan-refractory mCRC who were treated was tested for immunoreactivity (ie, immunohistochemistry; IHC), pAKT IHC, mutations. Analyses performed both primary tumors related...
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination gemcitabine and cisplatin patients advanced biliary tract cancer. present study investigated efficacy safety of this new standard treatment real‐world setting. Methods analysed population included unresectable, locally or metastatic adenocarcinoma treated at 17 Italian centres. primary endpoint was progression‐free (PFS), whereas...
Purpose We hypothesized that the detection of epidermal growth factor receptor (EGFR) expression performed in primary tumors for treatment with EGFR-targeted monoclonal antibodies could not always correlate EGFR status metastatic sites, thus making cancer cells these sites resistant to therapy. The aim our study was on and related metastases order find out whether assessing is be considered an effective tool planning antibodies. Patients Methods retrospectively evaluated immunohistochemistry...
Although new treatment modalities changed the global approach to hepatocellular carcinoma (HCC), this disease still represents a medical challenge. Currently, therapeutic stronghold is sorafenib, tyrosine kinase inhibitor (TKI) directed against vascular endothelial growth factor (VEGF) family. Previous observations suggested that polymorphisms of VEGF and its receptor (VEGFR) genes may regulate angiogenesis lymphangiogenesis thus tumour control. The aim our study was evaluate role VEGFR in...
Mechanisms of acquired resistance to trastuzumab-based treatment in gastric cancer are largely unknown. In this study, we analyzed 22 pairs tumor samples taken at baseline and post-progression patients receiving chemotherapy trastuzumab for advanced HER2-positive [immunohistochemistry (IHC) 3+ or 2+ with in-situ hybridization (ISH) amplification] gastroesophageal cancers. Strict clinical criteria defining were adopted. Loss HER2 positivity loss over-expression defined as post-trastuzumab IHC...
In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect marker of hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Sorafenib represents the therapeutic stronghold advanced HCC patients. a tyrosine kinase inhibitor (TKI) mainly directed against angiogenetic pathway, correlation sorafenib administration...
We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte (PLR) with the aim to explored their prognostic value in patients advanced hepatocellular carcinoma (HCC) treated sorafenib. 56 HCC receiving sorafenib were available for our analysis. Lymphocyte, neutrophil platelet measured before beginning of treatment after one month. Patient SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) OS (5.6 13.9 = 0.027) respect...
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Immune checkpoint inhibitor (ICI)-based immunotherapy has significantly improved the survival of patients with advanced non-small cell lung cancer (NSCLC); however, a significant percentage do not benefit from this approach, and predictive biomarkers are needed. Increasing evidence demonstrates that cachexia, complex syndrome driven by cancer-related chronic inflammation often encountered in NSCLC, may impair immune response ICI efficacy. Herein, we carried out prospective study aimed at...
Importance Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge epidermal growth factor receptor (EGFR) inhibitors RAS wild-type (WT) MCRC may be valuable these patients. Objective To compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil alone as therapy WT MCRC. Design, Setting, and Participants This phase 2 randomized clinical trial (RCT) was conducted in 7 Italian centers from...